Impact of glycemic variability on cardiovascular outcomes beyond glycated hemoglobin. Evidence and clinical perspectives

Nutrition, Metabolism and Cardiovascular Diseases

Volumn 22, Issue 9, 2012, Pages 691-696

  Picconi, F ^a   Di Flaviani, A ^a   Malandrucco, I ^a   Giordani, I ^a   Frontoni, S ^a  

^a UNIVERSITY OF ROME TOR VERGATA   (Italy)

Author keywords

Cardiovascular outcomes; Glucose variability; Oxidative stress

Indexed keywords

GLYCOSYLATED HEMOGLOBIN;

CARDIOVASCULAR DISEASE; EVIDENCE BASED MEDICINE; GLUCOSE BLOOD LEVEL; HUMAN; INSULIN DEPENDENT DIABETES MELLITUS; NON INSULIN DEPENDENT DIABETES MELLITUS; OXIDATIVE STRESS; PATHOPHYSIOLOGY; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW;

BLOOD GLUCOSE; CARDIOVASCULAR DISEASES; DIABETES MELLITUS, TYPE 1; DIABETES MELLITUS, TYPE 2; EVIDENCE-BASED MEDICINE; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; OXIDATIVE STRESS; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

ANIMALIA;

EID: 84865740789     PISSN: 09394753     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.numecd.2012.03.006     Document Type: Review

References (53)

1. Standl E., Schnell O., Ceriello A. Postprandial hyperglycemia and glycemic variability - should we care. Diabetes Care 2011, 34(Suppl2):S120-S127.
2. Muggeo M., Zoppini G., Bonora E., Brun E., Bonadonna R.C., Moghetti P., et al. Fasting plasma glucose variability predicts 10-year survival of type 2 diabetic patients: the Verona Diabetes Study. Diabetes Care 2000, 23(1):45-50.
3. Cavalot F., Petrelli A., Traversa M., Bonomo K., Fiora E., Conti M., et al. Postprandial blood glucose is a stronger predictor of cardiovascular events than fasting blood glucose in type 2 diabetes mellitus, particularly in women: lessons from the San Luigi Gonzaga Diabetes Study. J Clin Endocrinol Metab 2006, 91:813-819.
4. Cavalot F., Pagliarino A., Valle M., Di Martino L., Bonomo K., Massucco P., et al. Postprandial blood glucose predicts cardiovascular events and all-cause mortality in type 2 diabetes in a 14-year follow-up: lessons from the San Luigi Gonzaga Diabetes Study. Diabetes Care 2011, 34(10):2237-2243.
5. Borg R., Kuenen J.C., Carstensen B., Zheng H., Nathan D.M., Heine R.J., ADAG Study Group, et al. HbA1(c) and mean blood glucose show stronger associations with cardiovascular disease risk factors than do postprandial glycaemia or glucose variability in persons with diabetes: the A1C-Derived Average Glucose (ADAG) study. Diabetologia 2011, 54:69-72.
6. Wadén J., Forsblom C., Thorn L.M., Gordin D., Saraheimo M., Groop P.H., Finnish Diabetic Nephropathy Study Group A1C variability predicts incident cardiovascular events, microalbuminuria, and overt diabetic nephropathy in patients with type 1 diabetes. Diabetes 2009, 58(11):2649-2655.
7. Nalysnyk L., Hernandez-Medina M., Krishnarajah G. Glycaemic variability and complications in patients with diabetes mellitus: evidence from a systematic review of the literature. Diabetes Obes Metab 2010, 12(4):288-298.
8. Kilpatrick E.S., Rigby A.S., Atkin S.L. The effect of glucose variability on the risk of microvascular complications in type 1 diabetes. Diabetes Care 2006, 29:1486-1490.
9. Wang C., Lv L., Yang Y., Chen D., Liu G., Chen L., et al. Glucose fluctuations in subjects with normal glucose tolerance, impaired glucose regulation and newly-diagnosed type 2 diabetes mellitus. Clin Endocrinol (Oxf) 2011, 10.1111/j.1365-2265.2011.04205.x.
10. The Diabetes Control and Complications Trial (DCCT) Research Group The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin dependent diabetes mellitus. N Engl J Med 1993, 329:977-986.
11. Lachin J.M., Genuth S., Nathan D.M., Zinman B., Rutledge B.N. The effect of glycemic exposure on the risk of microvascular complications in the diabetes control and complications trial - revisited. Diabetes 2008, 57(4):995-1001.
12. Borg R., Kuenen C.J., Carstensen B., Zheng H., Nathan D.N., Heine R.J., on behalf of the ADAG Study Group, et al. Associations between features of glucose exposure and A1C The A1C-Derived Average Glucose (ADAG) study. Diabetes 2010, 59:1585-1590.
13. Monnier L., Lapinski H., Colette C. Contributions of fasting and postprandial plasma glucose increments to the overall diurnal hyperglycemia of type 2 diabetic patients: variations with increasing levels of HbA1c. Diabetes Care 2003, 26(3):881-885.
14. Monnier L., Colette C., Owens D.R. Integrating glycaemic variability in the glycaemic disorders of type 2 diabetes: a move toward a unified glucose tetrad concept. Diabetes Metab Res Rev 2009, 25:393-402.
15. Monnier L., Colette C., Dunseath G., Owens D. The loss of postprandial glycemic control precedes stepwise deterioration of fasting with worsening diabetes. Diabetes Care 2007, 30(2):263-269.
16. DECODE Study Group, the European Diabetes Epidemiology Group Glucose tolerance and cardiovascular mortality: comparison of fasting and 2-hour diagnostic criteria. Arch Intern Med 2001, 161:397-405.
17. Kilpatrick E.S. Arguments for and against the role of glucose variability in the development of diabetes complications. Diabetes Sci Technol 2009, 3(4):649-655.
18. Kohnert K.D., Augstein P., Heinke P., Zander E., Peterson K., Freyse E.J., et al. Chronic hyperglycemia but not glucose variability determines HbA1c levels in well-controlled patients with type 2 diabetes. Diabetes Res Clin Pract 2007, 77(3):420-426.
19. Hill N.R., Oliver N.S., Choudhary P., Levy J.C., Hindmarsh P., Matthews D.R. Normal reference range for mean tissue glucose and glycemic variability derived from continuous glucose monitoring for subjects without diabetes in different ethnic groups. Diabetes Technol Ther 2011, 13(9):921-928.
20. Wojcicki J.M. "J" -index. A new proposition of the assessment of current glucose control in diabetic patients. Horm Metab Res 1995, 27:41-42.
21. Cameron F.G., Donath M.D., Baghurst P.A. Measuring glycaemic variation. Curr Diabetes Rev 2010, 6(1):17-26.
22. Schlichtkrull J., Munck O., Jersild M. The M-value, an index of blood sugar control in diabetics. Acta Med Scand 1965, 177:95-102.
23. Kovatchev B.P., Clarke W.L., Breton M., Brayman K., McCall A. Quantifying temporal glucose variability in diabetes via continuous glucose monitoring: mathematical methods and clinical application. Diabetes Technol Ther 2005, 7:849-862.
24. Kovatchev B.P., Cox D.J., Kumar A., Gonder-Frederick L., Clarke W.L. Algorithmic evaluation of metabolic control and risk of severe hypoglycemia in type 1 and type 2 diabetes using self-monitoring blood glucose data. Diabetes Technol Ther 2003, 5:817-828.
25. Service F.J., Molnar G.D., Rosevear J.W., Ackerman E., Gatewood L.C., Taylor W.F. Mean amplitude of glycemic excursions, a measure of diabetic instability. Diabetes 1970, 19:644-655.
26. Monnier L., Colette C., Boegner C., Pham T.C., Lapinski H., Boniface H. Continuous glucose monitoring in patients with type 2 diabetes: why? when? whom?. Diabetes Metab 2007, 33:247-252.
27. Hill N.R., Hindmarsh P.C., Stevens R.J., Stratton I.M., Levy J.C., Matthews D.R. A method for assessing quality of control from glucose profiles. Diabet Med 2007, 24:753-758.
28. McDonnell C.M., Donath S.M., Vidmar S.I., Werther G.A., Cameron F.J. A novel approach to continuous glucose analysis utilizing glycemic variation. Diabetes Technol Ther 2005, 7:253-263.
29. Hermanides J., Vriesendorp T.M., Bosman R.J., Zandstra D.F., Hoekstra J.B., Devries J.H. Glucose variability is associated with intensive care unit mortality. Crit Care Med 2010, 38:838-842.
30. Risso A., Mercuri F., Quagliaro L., Damante G., Ceriello A. Intermittent high glucose enhances apoptosis in human. Am J Physiol Endocrinol Metab 2001, 281:E924-E930.
31. Quagliaro L., Piconi L., Assaloni R., Martinelli L., Motz E., Ceriello A. Intermittent high glucose enhances apoptosis related to oxidative stress in human umbilical vein endothelial cells: the role of protein kinase C and NAD(P)H-oxidase activation. Diabetes 2003, 52(11):2795-2804.
32. Horváth E.M., Benko R., Kiss L., Murányi M., Pék T., Fekete K., et al. Rapid 'glycaemic swings' induce nitrosative stress, activate poly- (ADP-ribose) polymerase and impair endothelial function in a rat model of diabetes mellitus. Diabetologia 2009, 52:952-961.
33. Biscetti F., Pitocco D., Straface G., Zaccardi F., de Cristofaro R., Rizzo P., et al. Glycaemic variability affects ischaemia-induced angiogenesis in diabetic mice. Clin Sci (Lond) 2011, 121(12):555-564.
34. Santilli F., Formoso G., Sbraccia P., Averna M., Miccoli R., Di Fulvio P., et al. Postprandial hyperglycemia is a determinant of platelet activation in early type 2 diabetes mellitus. J Thromb Haemost 2010, 8(4):828-837.
35. Monnier L., Mas E., Ginet C., Michel F., Villon L., Cristol J.P., et al. Activation of oxidative stress by acute glucose fluctuations compared with sustained chronic hyperglycemia in patients with type 2 diabetes. JAMA 2006, 295:1681-1687.
36. Wentholt I.M., Kulik W., Michels R.P., Hoekstra J.B., DeVries J.H. Glucose fluctuations and activation of oxidative stress in type 1 diabetes patients. Diabetologia 2008, 51:183-190.
37. Siegelaar S.E., Barwari T., Kulik W., Hoekstra J.B., DeVries H.J. No relevant relationship between glucose variability and oxidative stress in well-regulated type 2 diabetes patients. J Diabetes Sci Technol 2011, 5(1):86-92.
38. Ceriello A., Esposito K., Piconi L., Ihnat M.A., Thorpe J.E., Testa R., et al. Oscillating glucose is more deleterious to endothelial function and oxidative stress than mean glucose in normal and type 2 diabetic patients. Diabetes 2008, 57:1349-1354.
39. Siegelaar S.E., Holleman F., Hoekstra J.B.L., DeVries J.H. Glucose variability; does it matter?. Endocr Rev 2010, 31(2):171-182.
40. Meigs J.B., Nathan D.M., D'Agostino R.B., Wilson P.W., Framingham Offspring Study Fasting and postchallenge glycemia and cardiovascular disease risk: the Framingham offspring study. Diabetes Care 2002, 25:1845-1850.
41. Levitan E.B., Song Y., Ford E.S., Liu S. Is nondiabetic hyperglycemia a risk factor for cardiovascular disease? a meta-analysis of prospective studies. Arch Intern Med 2004, 164:2147-2155.
42. Ceriello A., Esposito K., Piconi L., Ihnat M., Thorpe J., Testa R., et al. Glucose "peak" and glucose "spike": impact on endothelial function and oxidative stress. Diabetes Res Clin Pract 2008, 82:262-267.
43. Esposito K., Ciotola M., Carleo D., Schisano B., Sardelli L., Di Tommaso D., et al. Post-meal glucose peaks at home associate with carotid intima-media thickness in type 2 diabetes. J Clin Endocrinol Metab 2008, 93(4):1345-1350.
44. Ceriello A., Quagliaro L., Piconi L., Assaloni R., Da Ros R., Maier A., et al. Effect of postprandial hypertriglyceridemia and hyperglycemia on circulating adhesion molecules and oxidative stress generation and the possible role of simvastatin treatment. Diabetes 2004, 53(3):701-710.
45. Hanefeld M., Fischer S., Julius U., Schulze J., Schwanebeck U., Schmechel H., et al. Risk factors for myocardial infarction and death in newly detected NIDDM: the Diabetes Intervention Study, 11-year follow-up. Diabetologia 1996, 39:1577-1583.
46. Chiasson J.L., Josse R.G., Gomis R., Hanefeld M., Karasik A., Laakso M. Acarbose treatment and the risk of cardiovascular disease and hypertension in patients with impaired glucose tolerance: the STOP-NIDDM Trial. JAMA 2003, 290:486-494.
47. Hanefeld M., Cagatay M., Petrowitsch T., Neuser D., Petzinna D., Rupp M. Acarbose reduces the risk for myocardial infarction in type 2 diabetic patients: meta-analysis of seven long-term studies. Eur Heart J 2004, 25(1):10-16.
48. The Navigator Study Group Effect of nateglinide on the incidence of diabetes and cardiovascular events. New Engl J Med 2010, 362(16):1463-1476.
49. Raz I., Wilson P.W., Strojek K., Kowalska I., Bozikov V., Gitt A.K., et al. Effects of prandial versus fasting glycemia on cardiovascular outcomes in type 2 diabetes: the HEART2D trial. Diabetes Care 2009, 32(3):381-386.
50. Siegelaar S.E., Kerr L., Jacober S.J., Devries J.H. A decrease in glucose variability does not reduce cardiovascular event rates in type 2 diabetic patients after acute myocardial infarction: a reanalysis of the HEART2D study. Diabetes Care 2011, 34(4):855-857.
51. Monnier L., Colette C. Glycemic variability: can we bridge the divide between controversies?. Diabetes Care 2011, 34(4):1058-1059.
52. Monnier L., Colette C., Mas E., Michel F., Cristol J.P., Boegner C., et al. Regulation of oxidative stress by glycaemic control: evidence for an independent inhibitory effect of insulin therapy. Diabetologia 2010, 53(3):562-571.
53. Di Flaviani A., Picconi F., Di Stefano P., Giordani I., Malandrucco I., Maggio P., et al. Impact of glycemic and blood pressure variability on surrogate measures of cardiovascular outcomes in type 2 diabetic patients. Diabetes Care 2011, 34(7):1605-1609.